United Therapeutics UTHR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.6%-1.3pp | 87.9%-0.7pp | 88.6%-0.4pp | 89%0.0pp | 89%-0.2pp | |
| Operating margin | 45.3%-1.6pp | 46.9%-0.8pp | 47.7%+0.7pp | 47%+0.2pp | 46.9%-1.0pp | |
| Net margin | 40.6%-1.3pp | 41.9%+1.3pp | 40.7%+0.3pp | 40.4%-0.1pp | 40.4%-1.1pp | |
| Returns | ||||||
| Return on equity | 20.3%+0.5pp | 19.7%-0.3pp | 20%+0.7pp | 19.3%-0.6pp | 19.9%+0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.8×-1.8× | 6.6×+0.2× | 6.4×-0.9× | 7.3×+1.8× | 5.5×+0.2× | |
| Per Share | ||||||
| Book value per share | $125.02-15.6% | $148.15+6.3% | $139.33-6.2% | $148.52+6.0% | $140.07+5.4% | |
| Valuation | ||||||
| Market capitalization | $25.99B+23.9% | $20.98B+10.7% | $18.96B+45.0% | $13.08B-5.5% | $13.85B-12.1% | |
| Price / earnings | 20.2×+4.5× | 15.7×+0.8× | 14.9×+4.4× | 10.5×-0.9× | 11.4×-1.7× | |
| Price / sales | 8.2×+1.6× | 6.6×+0.5× | 6.1×+1.8× | 4.2×-0.4× | 4.6×-0.9× | |
| Price / book | 4.4×+1.4× | 3×+0.1× | 2.9×+1.1× | 1.8×-0.2× | 2×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are United Therapeutics's profit margins?
- United Therapeutics (UTHR) runs a 86.6% gross margin and a 45.3% operating margin, with a 40.6% net margin.
- Where do United Therapeutics's ratios come from?
- Every ratio is computed from United Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
